Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Single-cell exomes in an index case of amp1q21 multiple myeloma reveal more diverse mutanomes than the whole population.

Bryant D, Tapper W, Weston-Bell NJ, Bolomsky A, Song L, Xu S, Collins AR, Zojer N, Sahota SS.

Blood. 2018 Jul 12;132(2):232-235. doi: 10.1182/blood-2018-01-829291. Epub 2018 May 18. No abstract available.

2.

Fixed duration vs continuous therapy in multiple myeloma.

Ludwig H, Zojer N.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):212-222. doi: 10.1182/asheducation-2017.1.212. Review.

3.

Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.

Bolomsky A, Heusschen R, Schlangen K, Stangelberger K, Muller J, Schreiner W, Zojer N, Caers J, Ludwig H.

Haematologica. 2018 Feb;103(2):325-335. doi: 10.3324/haematol.2017.172973. Epub 2017 Nov 9.

4.

My personal highlights of ESMO 2016.

Dediu M, Gerger A, Zojer N, Bartsch R.

Memo. 2017;10(1):46-47. doi: 10.1007/s12254-017-0314-8. Epub 2017 Feb 8.

5.

IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.

Bolomsky A, Hübl W, Spada S, Müldür E, Schlangen K, Heintel D, Rocci A, Weißmann A, Fritz V, Willheim M, Zojer N, Palumbo A, Ludwig H.

Am J Hematol. 2017 Mar;92(3):269-278. doi: 10.1002/ajh.24634. Epub 2017 Feb 1.

6.

The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K.

Haematologica. 2016 Dec;101(12):1451-1459. Epub 2016 Nov 10. Review.

7.

Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.

Worel N, Fritsch G, Agis H, Böhm A, Engelich G, Leitner GC, Geissler K, Gleixner K, Kalhs P, Buxhofer-Ausch V, Keil F, Kopetzky G, Mayr V, Rabitsch W, Reisner R, Rosskopf K, Ruckser R, Zoghlami C, Zojer N, Greinix HT.

J Clin Apher. 2017 Aug;32(4):224-234. doi: 10.1002/jca.21496. Epub 2016 Aug 31.

PMID:
27578390
8.

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).

Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, Dimopoulos MA, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, Dávid M, de la Rubia J, Drach J, Gasztonyi Z, Górnik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H.

Leukemia. 2017 Jan;31(1):107-114. doi: 10.1038/leu.2016.176. Epub 2016 Jun 24.

9.

Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma.

Bolomsky A, Schreder M, Hübl W, Zojer N, Hilbe W, Ludwig H.

Leuk Lymphoma. 2016 Nov;57(11):2516-25. doi: 10.3109/10428194.2016.1151511. Epub 2016 Mar 21.

PMID:
26999330
10.

Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.

Bolomsky A, Schlangen K, Schreiner W, Zojer N, Ludwig H.

J Hematol Oncol. 2016 Mar 2;9:17. doi: 10.1186/s13045-016-0247-4.

11.

The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.

Caers J, Fernández de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastritis E, Minnema M, Jurczyszyn A, Beguin Y, Wäsch R, Palumbo A, Dimopoulos M, Mateos MV, Ludwig H, Engelhardt M.

Oncologist. 2016 Mar;21(3):333-42. doi: 10.1634/theoncologist.2015-0303. Epub 2016 Feb 26. Review.

12.

Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.

Ludwig H, Milosavljevic D, Berlanga O, Zojer N, Hübl W, Fritz V, Harding S.

Am J Hematol. 2016 Mar;91(3):295-301. doi: 10.1002/ajh.24268.

13.

Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma.

Cowan G, Weston-Bell NJ, Bryant D, Seckinger A, Hose D, Zojer N, Sahota SS.

Oncotarget. 2015 May 30;6(15):13229-40.

14.

Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.

Bolomsky A, Hose D, Schreder M, Seckinger A, Lipp S, Klein B, Heintel D, Ludwig H, Zojer N.

J Hematol Oncol. 2015 Feb 8;8:10. doi: 10.1186/s13045-014-0105-1.

15.

Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

Ludwig H, Rauch E, Kuehr T, Adam Z, Weißmann A, Kasparu H, Autzinger EM, Heintel D, Greil R, Poenisch W, Müldür E, Zojer N.

Haematologica. 2015 Mar;100(3):385-91. doi: 10.3324/haematol.2014.115204. Epub 2014 Nov 14.

16.

Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro.

Bolomsky A, Schreder M, Meißner T, Hose D, Ludwig H, Pfeifer S, Zojer N.

Exp Hematol. 2014 Jul;42(7):516-25. doi: 10.1016/j.exphem.2014.03.005. Epub 2014 Apr 2.

PMID:
24704163
17.

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weißmann A, Adam Z.

Blood. 2014 Feb 13;123(7):985-91. doi: 10.1182/blood-2013-08-521468. Epub 2013 Nov 13.

18.

Cereblon expression in multiple myeloma: not ready for prime time - response to Lodé et al.

Zojer N, Heintel D, Palumbo A, Ludwig H.

Br J Haematol. 2013 Oct;163(2):285-6. doi: 10.1111/bjh.12477. Epub 2013 Jul 19. No abstract available.

PMID:
23869521
19.

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.

Heintel D, Rocci A, Ludwig H, Bolomsky A, Caltagirone S, Schreder M, Pfeifer S, Gisslinger H, Zojer N, Jäger U, Palumbo A.

Br J Haematol. 2013 Jun;161(5):695-700. doi: 10.1111/bjh.12338. Epub 2013 Apr 9.

PMID:
23565715
20.

Exome sequencing in tracking clonal evolution in multiple myeloma following therapy.

Weston-Bell N, Gibson J, John M, Ennis S, Pfeifer S, Cezard T, Ludwig H, Collins A, Zojer N, Sahota SS.

Leukemia. 2013 Apr;27(5):1188-91. doi: 10.1038/leu.2012.287. Epub 2012 Oct 9. No abstract available.

PMID:
23147253
21.

Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.

Ludwig H, Milosavljevic D, Zojer N, Faint JM, Bradwell AR, Hübl W, Harding SJ.

Leukemia. 2013 Jan;27(1):213-9. doi: 10.1038/leu.2012.197. Epub 2012 Jul 17. Erratum in: Leukemia. 2013 Apr;27(4):996.

22.

Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth.

Pfeifer S, Schreder M, Bolomsky A, Graffi S, Fuchs D, Sahota SS, Ludwig H, Zojer N.

J Cancer Res Clin Oncol. 2012 Nov;138(11):1821-30. doi: 10.1007/s00432-012-1259-2. Epub 2012 Jun 22.

PMID:
22722711
23.

Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.

Mirzaei S, Bastati B, Lipp RW, Knoll P, Zojer N, Ludwig H.

Oncology. 2011;80(5-6):326-9. doi: 10.1159/000329808. Epub 2011 Jul 25.

PMID:
21791941
24.

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.

Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H, Bartlett JB, Schafer PH, Schreder M, Bolomsky A, Hilgarth B, Zojer N, Gisslinger H, Ludwig H, Daniel T, Jäger U, Chopra R.

Br J Haematol. 2011 Aug;154(3):325-36. doi: 10.1111/j.1365-2141.2011.08689.x. Epub 2011 Jun 24.

PMID:
21707574
25.

Supportive therapy in multiple myeloma.

Ludwig H, Zojer N.

Recent Results Cancer Res. 2011;183:307-33. doi: 10.1007/978-3-540-85772-3_15. Review.

PMID:
21509692
26.

Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis.

Pfeifer S, Perez-Andres M, Ludwig H, Sahota SS, Zojer N.

Leukemia. 2011 Jul;25(7):1213-6. doi: 10.1038/leu.2011.70. Epub 2011 Apr 15. No abstract available.

PMID:
21494259
27.

Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.

Fiegl M, Falkner F, Steurer M, Zojer N, Hopfinger G, Haslbauer F, Winder G, Voskova D, Andel J, Lang A, Brychtova Y, Mayer J, Greil R, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia; Czech Leukemia Study Group for Life; CELL.

Ann Hematol. 2011 Sep;90(9):1083-91. doi: 10.1007/s00277-011-1192-5. Epub 2011 Feb 25.

PMID:
21350830
28.

Patient with high-grade fever, night sweats, and hepatosplenomegaly.

Müldür E, Chott A, Mirzaei S, Zojer N, Ludwig H.

J Clin Oncol. 2011 Apr 1;29(10):e254-6. doi: 10.1200/JCO.2010.32.6330. Epub 2011 Jan 10. No abstract available.

PMID:
21220615
29.

Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.

Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT.

Transfusion. 2011 May;51(5):968-75. doi: 10.1111/j.1537-2995.2010.02896.x. Epub 2010 Sep 28.

PMID:
20880037
30.

DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.

Joseph-Pietras D, Gao Y, Zojer N, Ait-Tahar K, Banham AH, Pulford K, Rice J, Savelyeva N, Sahota SS.

Leukemia. 2010 Nov;24(11):1951-9. doi: 10.1038/leu.2010.196. Epub 2010 Sep 23.

PMID:
20861911
31.

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N.

J Clin Oncol. 2010 Oct 20;28(30):4635-41. doi: 10.1200/JCO.2010.28.1238. Epub 2010 Sep 7.

PMID:
20823423
32.

Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.

Lamm W, Willenbacher W, Lang A, Zojer N, Müldür E, Ludwig H, Schauer-Stalzer B, Zielinski CC, Drach J.

Ann Hematol. 2011 Feb;90(2):201-6. doi: 10.1007/s00277-010-1062-6. Epub 2010 Sep 7.

PMID:
20821326
33.

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.

Ludwig H, Adam Z, Tóthová E, Hajek R, Labar B, Egyed M, Spicka I, Gisslinger H, Drach J, Kuhn I, Hinke A, Zojer N.

Haematologica. 2010 Sep;95(9):1548-54. doi: 10.3324/haematol.2009.020586. Epub 2010 Apr 23.

34.

Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.

Ludwig H, Zojer N.

Nat Rev Clin Oncol. 2010 May;7(5):289-94. doi: 10.1038/nrclinonc.2010.31. Epub 2010 Mar 30.

PMID:
20351701
35.

Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma.

Lehnert M, Ludwig H, Zojer N.

Onco Targets Ther. 2009 Feb 18;2:199-208.

36.

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.

Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A.

Blood. 2009 Apr 9;113(15):3435-42. doi: 10.1182/blood-2008-07-169565. Epub 2008 Oct 27.

37.

Recent therapeutic advances in hematological malignancies: dealing with treatment-related complications.

Ludwig H, Zojer N.

Ann Oncol. 2008 Jul;19 Suppl 5:v71-8. doi: 10.1093/annonc/mdn315. No abstract available.

PMID:
18611905
38.

Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan.

Zojer N, Mirzaei S, Ludwig H.

Eur J Haematol. 2008 Oct;81(4):322-4. doi: 10.1111/j.1600-0609.2008.01107.x. Epub 2008 Jul 8.

PMID:
18616515
39.

Supportive care in multiple myeloma.

Ludwig H, Zojer N.

Best Pract Res Clin Haematol. 2007 Dec;20(4):817-35. Review.

PMID:
18070721
40.

Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma.

Ludwig H, Strasser-Weippl K, Schreder M, Zojer N.

Ann Oncol. 2007 Jul;18 Suppl 9:ix64-70. Review. No abstract available.

PMID:
17631598
41.

Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma.

Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M, Gisslinger H, Drach J, Gaiger A, Jäger U, Ludwig H.

Leukemia. 2008 Feb;22(2):441-5. Epub 2007 Aug 9. No abstract available.

PMID:
17690696
42.

[Anemias].

Zojer N, Ludwig H.

Wien Klin Wochenschr. 2006 Sep;118(17-18 Suppl 2):69-83; quiz 84. German. No abstract available.

PMID:
17598316
43.

Hematological emergencies.

Zojer N, Ludwig H.

Ann Oncol. 2007 Jan;18 Suppl 1:i45-i48. Review. No abstract available.

PMID:
17311822
44.

Supportive care.

Ludwig H, Zojer N.

Ann Oncol. 2007 Jan;18 Suppl 1:i37-i44. Review. No abstract available.

PMID:
17311821
45.

IgM-expressing Waldenstrom's macroglobulinemia tumor cells reveal a potential for isotype switch events in vivo.

Babbage G, Townsend M, Zojer N, Mockridge IC, Garand R, Barlogie B, Shaughnessy J Jr, Stevenson FK, Sahota SS.

Leukemia. 2007 Apr;21(4):827-30. Epub 2007 Feb 8. No abstract available.

PMID:
17287856
46.

Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System.

Sagaster V, Kaufmann H, Odelga V, Ackermann J, Gisslinger H, Rabitsch W, Zojer N, Ludwig H, Nösslinger T, Zielinski C, Drach J.

Eur J Haematol. 2007 Mar;78(3):227-34. Epub 2007 Jan 23.

PMID:
17253972
47.

PASD1 is a potential multiple myeloma-associated antigen.

Sahota SS, Goonewardena CM, Cooper CD, Liggins AP, Ait-Tahar K, Zojer N, Stevenson FK, Banham AH, Pulford K.

Blood. 2006 Dec 1;108(12):3953-5. No abstract available.

48.

Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia.

Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S, Fiegl M, Simonitsch-Klupp I, Gisslinger H, Zojer N, Ludwig H.

Cancer. 2006 Dec 15;107(12):2801-6.

49.

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.

Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, Küenburg E, Wieser R, Zielinski C, Drach J.

Leukemia. 2007 Jan;21(1):164-8. Epub 2006 Nov 9.

PMID:
17096015
50.

"Laying on of hands" improves well-being in patients with advanced cancer.

Pohl G, Seemann H, Zojer N, Ochsner C, Luhan C, Schemper M, Ludwig H.

Support Care Cancer. 2007 Feb;15(2):143-51. Epub 2006 Oct 13.

PMID:
17039380

Supplemental Content

Support Center